



PATENT

1624 #9
2/27/02
83

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Continuation application of: Bergnes et al.

Attorney Docket No.: CYTOP009C5

Application No.: 09/724,897 ✓

Examiner: UNASSIGNED

Filed: November 28, 2000 ✓

Group: 1624

Title: METHODS AND COMPOSITIONS
UTILIZING QUINAZOLINONES ✓

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the
United States Postal Service as First Class Mail to: Commissioner for
Patents, Washington, DC 20231 on November 15, 2001.

Signed: _____

Laura M. Dean

BEST AVAILABLE COPY

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.56 AND 1.97(c)

Commissioner for Patents
Washington, DC 20231

RECEIVED
JAN 17 2001
TECH CENTER 1600/2900

Dear Sir:

The references listed in the attached PTO Form 1449 may be material to examination of the above-identified patent application. Applicants submit the list of these references in compliance with their duty of disclosure pursuant to 37 CFR §§1.56 and 1.97. The Examiner is requested to make these references of official record in this application. The above-identified application is a continuation of prior application U.S. Patent Application No. 09/699,047. This prior application is being relied upon for an earlier filing date under 35 U.S.C. § 120. Because the listed references were either cited by the PTO, or submitted to the PTO in the prior application, under 37 CFR § 1.98(d) Applicants submit that copies need not be provided.

This Information Disclosure Statement is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these references indeed constitute prior art.

This Information Disclosure Statement is: (i) filed within three (3) months of the filing date of the above-referenced application, (ii) believed to be filed before the mailing date of a first Office Action on the merits, or (iii) believed to be filed before the mailing of a first Office Action after the filing of a Request for Continued Examination under §1.114. Accordingly, it is believed that no fees are due in connection with the filing of this Information Disclosure

Statement. However, if it is determined that any fees are due, the Commissioner is hereby authorized to charge such fees to Deposit Account 50-1339 (Order No. CYTOP009C5).

Respectfully submitted,

BEYER WEAVER & THOMAS, LLP

A handwritten signature in black ink, appearing to read "Lauren L. Stevens", followed by a checkmark.

Lauren L. Stevens

Registration No. 36,691

P.O. Box 778

Berkeley, CA 94704-0778

BEST AVAILABLE COPY